What action is the Minister taking to ensure eligible people with migraines can access NICE-approved calcitonin gene-related peptide antibody medicines?
Erenumab, Fremanezumab and Galcanezumab are human monoclonal antibody medicines that bind to the calcitonin gene-related peptide (CGRP) receptor, inhibiting the function of CGRP, and thereby preventing migraine attacks.
Erenumab has been available in Wales through the New Treatment Fund since 11 December 2020. Fremanezumab has been available since 12 March 2020. Galcanezumab has been available since 15 October 2020.
However, when NICE recommended them they did so with restrictions, which are outlined in the links below.
Further information on Erenumab can be found here: https://www.nice.org.uk/guidance/ta682/informationforpublic
Further information on Fremanezumab can be found here:
https://www.nice.org.uk/guidance/ta631/informationforpublic
Further information on Galcanezumab can be found here: